New combo aims to keep advanced lung cancer in check
NCT ID NCT07459634
First seen Mar 11, 2026 · Last updated May 13, 2026 · Updated 8 times
Summary
This study tests whether a combination of two drugs (lurbinectedin and durvalumab) can help keep extensive-stage small-cell lung cancer from growing after initial chemotherapy. About 50 adults whose cancer did not worsen after first treatment will receive this maintenance therapy. The goal is to see if the combination extends the time without cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Valkyrie Clinical Trials, Inc.
Los Angeles, California, 90067, United States
Conditions
Explore the condition pages connected to this study.